Epidemiology Insights and Forecast
Disease Burden insights, powered with real-world data
Thelansis provides robust epidemiology insights built on validated methodologies, real-world registries, healthcare utilization data, clinical literature, and expert review. Our Epidemiology Insights deliver a comprehensive understanding of disease burden, by prevalence, incidence, diagnosed cases, comorbidities, clinical manifestations and severity stratification across geographies. This help quantify the true patient population, disease progression, and forecast trends across major global markets.
What We Provide:
- 8 MM/20+ Country Epidemiology Forecasts
- Prevalence, Incidence, Mortality & Survival Estimates
- Population Segmentation by Stage, Biomarker, Severity & Line of Therapy
- Prognostic Subgroup Analysis for targeted therapies
- Population Flow Models (undiagnosed → diagnosed → treated → eligible)
- Methodology Based on Published Literature, Registries & Expert Validation
How It Helps You:
Accurate epidemiology is essential for:
- Opportunity assessment and market sizing
- Clinical development planning
- Reimbursement dossiers
- Commercial strategy and resource allocation
- Health technology assessments (HTA)
What Strategic Answers Clients Will Receive:
- How large is the patient population today (incidence, prevalence, segments)?
- How will the epidemiology evolve over time, and what factors will drive those changes?
- What are the key patient subgroups by stage, biomarker, severity, and treatment status?
- How does patient progression flow across the disease continuum?
- What is the realistic addressable patient pool for current and future therapies?
- How do epidemiology trends differ across the US, EU5, Japan, China, and other 20+ emerging markets?
Reports:
Market Access and Reimbursement Insights
Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Market Access and Reimbursement Insights
Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Market Access and Reimbursement Insights
Thelansis’s “Relapsed or Refractory Non-Hodgkin lymphoma (r/r NHL) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Emerging Therapy, Unmet Needs and TPP Insights
Thelansis’s “Relapsed or Refractory Non-Hodgkin lymphoma (r/r NHL) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Need customize support?
Thelansis also caters to your specific needs by providing customized reports that satisfy your organizational requirements. Get on-demand customization of the report’s scope to exactly meet your needs.

